Cargando…

Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database

BACKGROUND: Psychotropic medications are useful to treat psychiatric disorders which are frequently underdiagnosed and undertreated in cancer patients. Evidence on utilisation of psychotropic medications in cancer patients was absent in China. This study aimed to analyse the prevalence and the poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Lin, Xu, Ziyue, Huang, Cong, Sui, Yunchuan, Guan, Xiaodong, Shi, Luwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315446/
https://www.ncbi.nlm.nih.gov/pubmed/34327398
http://dx.doi.org/10.1016/j.lanwpc.2020.100060
_version_ 1783729720023580672
author Bai, Lin
Xu, Ziyue
Huang, Cong
Sui, Yunchuan
Guan, Xiaodong
Shi, Luwen
author_facet Bai, Lin
Xu, Ziyue
Huang, Cong
Sui, Yunchuan
Guan, Xiaodong
Shi, Luwen
author_sort Bai, Lin
collection PubMed
description BACKGROUND: Psychotropic medications are useful to treat psychiatric disorders which are frequently underdiagnosed and undertreated in cancer patients. Evidence on utilisation of psychotropic medications in cancer patients was absent in China. This study aimed to analyse the prevalence and the potential predictors of psychotropic medication use in adult cancer patients in China. METHODS: We analysed cross-sectional data from the China Health Insurance Association database in 2015–2017, which contained health care utilisation information for a national representative sample of basic medical insurance beneficiaries. Cancer patients aged above 18 were identified by International Classification of Disease 10th revision code C00–C97. Psychotropic medications were defined following the Anatomical Therapeutic Chemical codes: antipsychotics (N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), and antidepressants (N06A, N06CA). We calculated the prevalence of psychotropic medication use in cancer patients, and applied multivariable logistic regression to identify its potential predictors. FINDINGS: A total of 260,364 adults with cancer were identified in the database, of which 48,111 (18•5%) were prescribed at least one psychotropic medication comprising antipsychotics (3763, 1•4%), anxiolytics (15,902, 6•1%), hypnotics and sedatives (37,040, 14•2%), and antidepressants (2379, 0•9%). Patients with solid tumours had higher prevalence of psychotropic medication use than patients with lymphoid and hematopoietic malignancies (e.g. female genital organs, adjusted odds ratio (OR)=2•25, 95%CI=2•09–2•44). The prevalence of psychotropic medication use in cancer patients in the Eastern region was significantly higher than those of cancer patients in the Western regions (OR=2•33, 95%CI=2•27–2•40). Compared with the Urban Rural Resident Basic Medical Insurance beneficiaries, cancer patients covered by the Urban Employee Basic Medical Insurance were more likely to use psychotropic medications (OR=1•18, 95%CI=1•15–1•20). Midazolam was the most frequently used psychotropic (21,728, 45•2%), and flupentixol–melitracen was the most commonly used antidepressant (1176, 2•4%) among all psychotropic medication users in the sample. INTERPRETATION: The prevalence of psychotropic medication use in Chinese adult cancer patients was inequitable. Further attention will be needed to be paid to the mental health of cancer patients in China. FUNDING: No funding.
format Online
Article
Text
id pubmed-8315446
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83154462021-07-28 Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database Bai, Lin Xu, Ziyue Huang, Cong Sui, Yunchuan Guan, Xiaodong Shi, Luwen Lancet Reg Health West Pac Research Paper BACKGROUND: Psychotropic medications are useful to treat psychiatric disorders which are frequently underdiagnosed and undertreated in cancer patients. Evidence on utilisation of psychotropic medications in cancer patients was absent in China. This study aimed to analyse the prevalence and the potential predictors of psychotropic medication use in adult cancer patients in China. METHODS: We analysed cross-sectional data from the China Health Insurance Association database in 2015–2017, which contained health care utilisation information for a national representative sample of basic medical insurance beneficiaries. Cancer patients aged above 18 were identified by International Classification of Disease 10th revision code C00–C97. Psychotropic medications were defined following the Anatomical Therapeutic Chemical codes: antipsychotics (N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), and antidepressants (N06A, N06CA). We calculated the prevalence of psychotropic medication use in cancer patients, and applied multivariable logistic regression to identify its potential predictors. FINDINGS: A total of 260,364 adults with cancer were identified in the database, of which 48,111 (18•5%) were prescribed at least one psychotropic medication comprising antipsychotics (3763, 1•4%), anxiolytics (15,902, 6•1%), hypnotics and sedatives (37,040, 14•2%), and antidepressants (2379, 0•9%). Patients with solid tumours had higher prevalence of psychotropic medication use than patients with lymphoid and hematopoietic malignancies (e.g. female genital organs, adjusted odds ratio (OR)=2•25, 95%CI=2•09–2•44). The prevalence of psychotropic medication use in cancer patients in the Eastern region was significantly higher than those of cancer patients in the Western regions (OR=2•33, 95%CI=2•27–2•40). Compared with the Urban Rural Resident Basic Medical Insurance beneficiaries, cancer patients covered by the Urban Employee Basic Medical Insurance were more likely to use psychotropic medications (OR=1•18, 95%CI=1•15–1•20). Midazolam was the most frequently used psychotropic (21,728, 45•2%), and flupentixol–melitracen was the most commonly used antidepressant (1176, 2•4%) among all psychotropic medication users in the sample. INTERPRETATION: The prevalence of psychotropic medication use in Chinese adult cancer patients was inequitable. Further attention will be needed to be paid to the mental health of cancer patients in China. FUNDING: No funding. Elsevier 2020-11-20 /pmc/articles/PMC8315446/ /pubmed/34327398 http://dx.doi.org/10.1016/j.lanwpc.2020.100060 Text en © 2020 The Author(s). Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Bai, Lin
Xu, Ziyue
Huang, Cong
Sui, Yunchuan
Guan, Xiaodong
Shi, Luwen
Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database
title Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database
title_full Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database
title_fullStr Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database
title_full_unstemmed Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database
title_short Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database
title_sort psychotropic medication utilisation in adult cancer patients in china: a cross-sectional study based on national health insurance database
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315446/
https://www.ncbi.nlm.nih.gov/pubmed/34327398
http://dx.doi.org/10.1016/j.lanwpc.2020.100060
work_keys_str_mv AT bailin psychotropicmedicationutilisationinadultcancerpatientsinchinaacrosssectionalstudybasedonnationalhealthinsurancedatabase
AT xuziyue psychotropicmedicationutilisationinadultcancerpatientsinchinaacrosssectionalstudybasedonnationalhealthinsurancedatabase
AT huangcong psychotropicmedicationutilisationinadultcancerpatientsinchinaacrosssectionalstudybasedonnationalhealthinsurancedatabase
AT suiyunchuan psychotropicmedicationutilisationinadultcancerpatientsinchinaacrosssectionalstudybasedonnationalhealthinsurancedatabase
AT guanxiaodong psychotropicmedicationutilisationinadultcancerpatientsinchinaacrosssectionalstudybasedonnationalhealthinsurancedatabase
AT shiluwen psychotropicmedicationutilisationinadultcancerpatientsinchinaacrosssectionalstudybasedonnationalhealthinsurancedatabase